GlassScriptPhysician profile
Aparna Prasad Shreenath
NPI 1184972747
$9,327.34
in general payments reported to CMS, 2019-2025
34 companies · $2,991 in 2025
The $2,991 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.41 · 2020: $22.58 · 2021: $126 · 2022: $1,570 · 2023: $2,151 · 2024: $2,395 · 2025: $2,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,462 · Education: $74.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,462.38 |
| Education | $74.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,240.00 | 2021-2025 | Rinvoq, Linzess, Viberzi |
| Genzyme Corporation | $778.58 | 2022-2025 | |
| Janssen Biotech, INC. | $717.10 | 2022-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $692.11 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.10 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $583.25 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $541.38 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $469.51 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $360.50 | 2023-2025 | Omvoh, Zepbound |
| Pfizer INC. | $306.43 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $271.98 | 2025 | Terlivaz |
| Madrigal Pharmaceuticals | $222.83 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $165.68 | 2022-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $151.17 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $148.34 | 2021-2024 | Dificid, Zinplava |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $144.79 | 2023-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $144.16 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $115.00 | 2024 | |
| Celgene Corporation | $95.42 | 2022-2024 | Zeposia |
| Olympus Corporation of The Americas | $71.41 | 2019 | |
| Celltrion USA INC. | $71.03 | 2023-2025 | Yuflyma, Zymfentra, Vegzelma |
| Regeneron Pharmaceuticals, INC. | $59.71 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $58.93 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $45.24 | 2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $39.38 | 2022 | |
| Organon LLC | $29.84 | 2023-2024 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $27.08 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Sandoz INC. | $19.17 | 2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $19.08 | 2025 | Tremfya |
| Axonics, INC. | $18.24 | 2024 | Axonics |
| Daiichi Sankyo INC. | $16.89 | 2022 | |
| Intra-Sana Laboratories | $15.53 | 2022 | |
| Biocon Biologics INC | $13.76 | 2024 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aparna Shreenath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.